Tirzepatide
GLP-1 / GIP dual agonist. Tirzepatide is FDA approved (Mounjaro, Zepbound); research-chemical versions are not the approved drug.
Key facts
- Class
- GLP-1 / GIP dual agonist
- Also called
- tirz, tirze
- Vial sizes sold
- 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg
- Community-reported sizes
- Half-life
- approximately 5 days
- subcutaneous, in people · FDA label (Mounjaro)
- FDA status
- Approved (Mounjaro, Zepbound)
- Approved
- WADA
- Not listed
- 2026 Prohibited List
Tirzepatide guides
Explained
Questions
Evidence at a glance
Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.
| Condition | Human studies | Animal studies | Studies we summarised | Evidence grade |
|---|---|---|---|---|
| Weight loss | 990 | 49 | 16 | Human RCT evidence, 4 of 4Arthritis & rheumatology 2026, PMID 41903163 |
| Sleep apnea | Not in our ledger | Not in our ledger | 1 | Human RCT evidence, 4 of 4The New England journal of medicine 2024, PMID 38912654 |
| Inflammation | 85 | 37 | 1 | No graded study for this goal |
| Diabetes | 843 | 48 | 8 | Human RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 41406444 |
| Energy | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Heart health | 358 | 11 | 7 | Human RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 41406444 |
| Sleep | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Muscle growth | Not in our ledger | Not in our ledger | 2 | Human RCT evidence, 4 of 4Diabetes, obesity & metabolism 2025, PMID 39996356 |
| Joint pain | 22 | 0 | 1 | Human RCT evidence, 4 of 4Arthritis & rheumatology 2026, PMID 41903163 |
| Lipedema | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Liver health | 143 | 15 | 3 | Human RCT evidence, 4 of 4The New England journal of medicine 2024, PMID 38856224 |
| Gut health | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Depression | 35 | 2 | 1 | Human RCT evidence, 4 of 4Obesity 2026, PMID 41537305 |
| Anxiety | 13 | 1 | 1 | Human RCT evidence, 4 of 4Obesity 2026, PMID 41537305 |
| Injury recovery | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Menopause | 8 | 7 | 0 | No graded study for this goal |
| Cognition | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Skin | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Bone health | 15 | 0 | 1 | Human observational evidence, 3 of 4Diabetes research and clinical practice 2025, PMID 41218687 |
| ADHD | 1 | 0 | 0 | No graded study for this goal |
| Thyroid | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Testosterone | Not in our ledger | Not in our ledger | 1 | Human RCT evidence, 4 of 4Reproductive biology and endocrinology 2025, PMID 40604795 |
| Libido | Not in our ledger | Not in our ledger | 1 | Human RCT evidence, 4 of 4Reproductive biology and endocrinology 2025, PMID 40604795 |
| Fertility | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Addiction | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Allergies | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Hormone balance | 6 | 4 | 1 | Human RCT evidence, 4 of 4Reproductive biology and endocrinology 2025, PMID 40604795 |
| Metabolism | 85 | 19 | 3 | Human RCT evidence, 4 of 4Diabetes, obesity & metabolism 2025, PMID 39996356 |
Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.
A dual agonist: GIP plus GLP-1
The label describes tirzepatide as acting on two receptors, GIP and GLP-1.[30]
The label says a modification of the molecule enables albumin binding, which prolongs its half-life.[30]
That half-life is approximately 5 days on the Zepbound label.[30]
Regulatory path
Drugs@FDA lists tirzepatide as an approved prescription drug; the cached record shows Mounjaro (60 mg/2.4 mL) with an original approval date of 20220513.[2]
In Canada, Health Canada lists the brand as Marketed.[31]
WADA's S0 catch-all applies only to substances with no government approval, so approved tirzepatide is outside it.[1]
Strongest finding, and what is still unsettled
The clearest head-to-head is a trial against semaglutide in obesity: -20.2% weight change on tirzepatide against -13.7% on semaglutide at week 72.[32]
In adults with obesity and obstructive sleep apnea, the apnea-hypopnea index fell by 25.3 events per hour in one trial, against 5.3 on placebo.[7]
Lean-mass preservation is a live question: a meta-analysis found the top tirzepatide and semaglutide doses were the most effective for fat loss but among the least effective at preserving lean mass.[33]
A large retrospective cohort linked tirzepatide to a higher osteoporosis risk than other GLP-1 drugs (hazard ratio 1.44); it is observational and does not show cause.[12]
Compared with
Common stacks
Tirzepatide is often sold pre-mixed or combined with other peptides. A few of these pairs appear together in published studies; each stack page lists what was tested, and the pages below cover the math and what each part has been studied for.
Common questions
Is Tirzepatide FDA approved?
Tirzepatide is FDA approved (Mounjaro, Zepbound). Products sold as research chemicals are not the approved drug and are not checked by the FDA.
How much water goes in a 10 mg vial?
That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.
What is tirzepatide?
A drug that activates both the GIP and GLP-1 receptors.[30]
How does tirzepatide work?
It binds to and activates both the GIP and GLP-1 receptors, the targets for the native hormones.[30]
What does tirzepatide do?
In the main obesity trial, mean weight change at week 72 reached -20.9% at the 15-mg dose versus -3.1% on placebo.[34]
Is there a tirzepatide pill?
The labelled tirzepatide product is an injection for subcutaneous use; no oral tirzepatide label appears in the cached records.[30]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2United States: Approved by FDA as Mounjaro (original approval 13 May 2022) and Zepbound (original approval 8 Nov 2023), both tirzepatide, Eli Lilly. Mounjaro is indicated for type 2 diabetes; Zepbound for chronic weight management and obstructive sleep apnea (see label quotes).U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 3FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 4FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 5Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 6Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
- 7Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.The New England journal of medicine · 2024PMID 38912654Accessed 2 Oct 2026
- 8Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.The New England journal of medicine · 2025PMID 41406444Accessed 2 Oct 2026
- 9Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.Diabetes, obesity & metabolism · 2025PMID 39996356Accessed 2 Oct 2026
- 10Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.The New England journal of medicine · 2024PMID 38856224Accessed 2 Oct 2026
- 11Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
- 12Association of tirzepatide use with risk of osteoporosis compared with other GLP-1 receptor agonists: A retrospective cohort study using the TriNetX database.Diabetes research and clinical practice · 2025PMID 41218687Accessed 2 Oct 2026
- 13Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity: a controlled pilot study.Reproductive biology and endocrinology : RB&E · 2025PMID 40604795Accessed 2 Oct 2026
- 14These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: tirzepatide[ti] AND (SURMOUNT[tiab] OR SURPASS[tiab]) AND randomized controlled trial[pt] (93 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16PubMed search: tirzepatide[ti] AND (SURPASS-2 OR SURPASS-3 OR SURPASS-4 OR SURPASS-5 OR "versus semaglutide" OR "SURPASS-CVOT" OR dulaglutide) (143 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17PubMed search: tirzepatide[ti] AND (steatohepatitis OR NASH OR "heart failure" OR HFpEF OR "preserved ejection" OR cardiovascular) (410 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 18PubMed search: tirzepatide[ti] AND (SURPASS-2 OR SURPASS-3 OR SURPASS-1 OR SURPASS-5 OR "SURPASS J-mono") AND randomized controlled trial[pt] (24 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 19PubMed search: tirzepatide[ti] AND (steatohepatitis OR "heart failure" OR "SUMMIT" OR "SYNERGY-NASH" OR "phase 2") AND randomized controlled trial[pt] (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 20PubMed search: tirzepatide[tiab] AND (meta-analysis[pt] OR systematic review[pt]) AND (weight OR glycemic OR HbA1c OR obesity) (178 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 21PubMed search: tirzepatide[tiab] AND (pharmacokinetic*[tiab] OR half-life[tiab]) AND humans[mh] (49 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 22PubMed search: tirzepatide[ti] AND (insulin degludec OR "SURPASS-3") AND "type 2 diabetes"[ti] AND randomized controlled trial[pt] (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 23PubMed search: tirzepatide[ti] AND (cardiovascular outcomes OR "SURPASS-CVOT" OR "major adverse") (228 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 24PubMed search: tirzepatide[tiab] AND (depression OR anxiety OR ADHD OR osteoporosis OR "bone mineral" OR menopause OR "rheumatoid" OR arthritis OR testosterone) (121 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 25PubMed search: tirzepatide[tiab] AND ("body composition"[tiab] OR "lean mass"[tiab] OR "visceral fat"[tiab] OR "fat mass"[tiab]) AND humans[mh] (91 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 26PubMed search: tirzepatide[tiab] AND (blood pressure[tiab] OR cholesterol[tiab] OR lipid*[tiab]) AND (randomized controlled trial[pt] OR meta-analysis[pt]) (58 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 27PubMed search: tirzepatide[tiab] AND (SURPASS-CVOT OR "cardiovascular events" ) AND "dulaglutide"[tiab] AND randomized controlled trial[pt] (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 28PubMed search: tirzepatide[tiab] AND (depression[tiab] OR anxiety[tiab] OR "mental health"[tiab] OR ADHD[tiab] OR "binge eating"[tiab]) AND (randomized controlled trial[pt] OR clinical trial[pt]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 29PubMed search: tirzepatide[tiab] AND (menopaus*[tiab] OR PCOS[tiab] OR "polycystic"[tiab] OR testosterone[tiab] OR hypogonadism[tiab]) (55 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 30ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 31Health Canada Drug Product Database search: ingredient name "tirzepatide"Health Canada · 2026health-products.canada.caAccessed 2 Oct 2026
- 32Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
- 33Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.Metabolism: clinical and experimental · 2025PMID 39719170Accessed 2 Oct 2026
- 34Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
Found an error? Report a correction.